The pharmacotherapy of sickle cell disease

Area of Science:

• Hematology
• Pharmacology

Background:

• Sickle cell disease (SCD) presents significant acute and chronic complications affecting multiple organ systems.
• Current treatments for SCD include red blood cell transfusions and hematopoietic stem cell transplantation.
• Recent advancements have expanded pharmacotherapeutic options for SCD management.

Purpose of the Study:

• To review recent progress in pharmacotherapy for sickle cell disease.
• To highlight the role of hydroxycarbamide in stimulating fetal hemoglobin (Hb F) production.
• To discuss emerging therapeutic strategies for SCD.

Main Methods:

• Review of current literature on sickle cell disease pharmacotherapy.
• Focus on agents stimulating Hb F production, such as hydroxycarbamide.
• Exploration of other therapeutic targets including ion channels, nitric oxide metabolism, coagulation, inflammation, and adhesion.

Main Results:

• Hydroxycarbamide is the only FDA-approved agent for SCD, effectively reducing vaso-occlusive pain events.
• Hydroxycarbamide is underutilized but has expanding indications through clinical trials.
• Other Hb F-promoting agents (decitabine, butyrate) and novel approaches are under investigation.

Conclusions:

• Pharmacotherapy for SCD has significantly advanced, offering alternatives to traditional treatments.
• Hydroxycarbamide remains a cornerstone therapy, with ongoing research to broaden its use.
• Future directions include exploring drug combinations and novel therapeutic targets for comprehensive SCD management.